Results 201 to 210 of about 3,204,753 (287)

Enhanced recovery after colorectal surgery in patients with inflammatory bowel disease to reduce hospital length of stay: A systematic review and meta‐analysis

Colorectal Disease, Volume 28, Issue 10, October 2026.
Abstract Aim Enhanced recovery after surgery (ERAS) improves outcomes in colorectal cancer surgery; however, patients with inflammatory bowel disease (IBD) have been relatively excluded from these analyses. The purpose of this systematic review was to evaluate the effects of ERAS protocols in adult patients with IBD.
Garrett Johnson, Evangelia Theodosopoulos, Jordyn Vernon, Selina Schmocker, Hilalion (San) Ahn, Javier Gomez, Mantaj S. Brar, Aman Pooni, Erin D. Kennedy   +8 more
wiley   +1 more source

Lived experiences of cancer care for people living with HIV who are treated for anal cancer: a scoping review. [PDF]

BMJ Open
Addington C, Davies N, Howell P, Cruickshank S, Hainsworth E.   +4 more
europepmc   +1 more source

A systematic review and meta‐analysis of preoperative MRI‐based pelvimetry in predicting surgical difficulty in rectal cancer: Implications for personalised surgical planning

Colorectal Disease, Volume 28, Issue 10, October 2026.
Abstract Background Magnetic resonance imaging (MRI)‐based pelvimetry has been investigated for predicting surgical difficulty in total mesorectal excision (TME) for rectal cancer. However, heterogeneity in pelvimetric parameters, surrogate outcomes, and study design has resulted in inconsistent evidence.
Daichi Kitaguchi, Fiona R. Kolbinger, Paul Dipanjyoti, Kshitij Jadhav, Tatsuya Oda, Antonello Forgione, Jacques Marescaux   +6 more
wiley   +1 more source

Anal cancer screening

Canadian Medical Association Journal
Grennan, Troy, Salit, Irving E.
openaire   +2 more sources

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 10, Page 1412-1416, October 2026.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Emotional support networks and discussion of anal cancer among sexual minority men in Nigeria: insights from an ego-centric analysis. [PDF]

BMC Public Health
Volpi CR, Chama J, Adebiyi R, Aigoro JA, Bawa YJ, Kolawole KE, Ononaku U, Ayuba N, Shutt A, Shin MB, Aka A, Goldstone SE, Dakum P, Palefsky JM, Adebajo S, Nowak RG, Tobin KE.   +16 more
europepmc   +1 more source

Tocilizumab for severe and refractory mucous membrane pemphigoid

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1682-1691, October 2026.
Elevated IL‐6 levels identified in mucous membrane pemphigoid support IL‐6 blockade, with tocilizumab demonstrating clinical benefit in nine patients with severe and refractory mucous membrane pemphigoid. Abstract Background Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially ...
Billal Tedbirt, Maud Maho‐Vaillant, Julie Gueudry, Marie‐Laure Golinski, Marion Marcaillou, Blanche Bergeret, Guillaume Chambon, Pierre Bouchetemble, Soumeya Bekri, Abdellah Tebani, Hervé Maillard, Cécile Morice, Anais Vautier, Edgar‐Pierre Libert, Christelle Le Roux‐Villet, Marion Carrette, Olivier Boyer, Vivien Hébert, Sébastien Calbo, André Gillibert, Pascal Joly   +20 more
wiley   +1 more source

Fournier's gangrene with anal cancer: a case report and literature review. [PDF]

J Surg Case Rep
Lee Y, Kim K, Park C, Lee J, Bae S, Baek S, Jeong W.   +6 more
europepmc   +1 more source

Design, Synthesis, and Biological Evaluation of Pyrazolyl Thioureas (PTUs) as SIRT1 and SIRT2 Inhibitors

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Pyrazolyl thioureas were designed and synthesized as sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) inhibitors. 6a (IC50 (SIRT1) = 5.3 µM; IC50 (SIRT2) = 2.2 µM) and 7f (IC50 (SIRT1) = 12.4 µM; IC50 (SIRT2) = 13.6 µM) showed micromolar inhibition on target enzymes and HepG2‐based assays confirmed a SIRT2‐mediated effect on tubulin acetylation. Docking studies
Matteo Lusardi, Cecilia Astigiano, Deianira Bellitto, Matteo Raineri, Giorgia Guccione, Annalisa Salis, Elena Cichero, Chiara Brullo, Marco Ponassi, Santina Bruzzone, Andrea Spallarossa   +10 more
wiley   +1 more source

Challenges and limitations of anal cancer and precancer screening among people with HIV in a real-world setting. [PDF]

Infection
Menzel V, Gruener E, Neuf J, Sammet S, Esser S, Roider J, Seybold U.   +6 more
europepmc   +1 more source